Carbonic Anhydrase IX targeted radioligand therapeutics for hypoxic solid tumors

Back to all technologies
Download as PDF
2022-LOW-69560
NCS: Researchers at Purdue University have discovered radiotherapeutics that target carbonic anhydrase IX (CA IX), a marker of hypoxia. Hypoxia is a common feature of solid tumors and develops because of poorly formed vasculature due to rapid growth of the tumor that outstrips the oxygen supply. Current radiotherapy treatments are non-specific and often toxic with severe side-effects. The Purdue researchers discovered small molecule ligands of CA IX to selectively bind it and deliver the radiotherapeutic.

Advantages
-Non-toxic
-Targeted therapy

Applications
-Solid tumor treatment
Sep 24, 2021
Provisional-Patent
United States
(None)
(None)
Purdue Office of Technology Commercialization
The Convergence Center
101 Foundry Drive, Suite 2500
West Lafayette, IN 47906

Phone: (765) 588-3475
Fax: (765) 463-3486
Email: otcip@prf.org